Nouriast (Parkinson’s Disease) - Forecast and Market Analysis to 2022

GlobalData
March 31, 2014
58 Pages - GLDATA18031
$3,495.00

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Istradefylline is a first-in-class adenosine A2 receptor inhibitor, marketed in Japan under the brand name Nouriast by Kyowa Hakko Kirin. It was approved in Japan for adjunct use with levodopa in advanced-stage patients with wearing-off in March 2013, and launched in May 2013 (Kyowa Hakko Kirin, press release, March 25, 2013; Kyowa Hakko Kirin, press release, May 29, 2013).

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Nouriast including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Nouriast for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Nouriast performance
- Obtain sales forecast for Nouriast from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

'

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 14
3.1.3 Prognosis 16
3.1.4 Quality of Life 17
3.2 Symptoms 17
4 Disease Management 19
4.1 Overview 19
4.1.1 Diagnosis - The UK Brain Bank Criteria 19
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.2 Treatment Synopsis 23
4.2.1 Dopaminergic Therapy Classes 23
4.2.2 Treatment of Parkinson’s Disease by Stage 25
4.2.3 Other Treatment Options 28
4.3 Parkinson’s Disease Assessment Scales 28
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 29
4.3.2 Hoehn and Yahr Clinical Staging 31
4.3.3 Other Clinical Assessments 32
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 35
5.3 Product Profiles - Adenosine 2A Inhibitor 37
6 Nouriast (istradefylline) 38
6.1 Overview 38
6.2 Efficacy 39
6.3 Safety 40
6.4 SWOT Analysis 40
6.5 Forecast 41
7 Appendix 42
7.1 Bibliography 42
7.2 Abbreviations 46
7.3 Methodology 49
7.4 Forecasting Methodology 49
7.4.1 Diagnosed Parkinson’s Disease Patients 49
7.4.2 Percent Drug-Treated Patients 50
7.4.3 General Pricing Assumptions 50
7.4.4 Compliance Assumptions 51
7.4.5 Individual Drug Assumptions 52
7.4.6 Generic Erosion 52
7.5 Physicians and Specialists Included in this Study 53
7.6 About the Authors 55
7.6.1 Author 55
7.6.2 Global Head of Healthcare 56
7.7 About GlobalData 57
7.8 Disclaimer 57

1.1 List of Tables
Table 1: Symptoms of Parkinson’s Disease 18
Table 2: UK Brain Bank Diagnostic Criteria 20
Table 3: Diagnosis and Treatment Guidelines for Parkinson’s Disease 21
Table 4: Most Prescribed Drugs for Parkinson’s Disease by Class in the Global Markets, 2014 22
Table 5: Dopaminergic Therapy in Parkinson’s Disease 25
Table 6: UPDRS Clinical Assessment of Disease Severity 30
Table 7: Parkinson’s Disease Assessment Scales Used in Clinical Trials 32
Table 8: Treatment of Motor Symptoms in Parkinson’s Disease 34
Table 9: Leading Treatments for Parkinson’s Disease, 2014 36
Table 10: Product Profile - Nouriast 39
Table 11: Nouriast SWOT Analysis, 2014 40
Table 12: Global Sales Forecasts ($m) for Nouriast, 2012-2022 41

1.2 List of Figures
Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes 24
Figure 2: Overview - Treatment of Motor Symptoms of Parkinson’s Disease 26

$3,495.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax